Weili, Xiaoying'en, I'll go all in first!

LintonBio, conclusion first: The wind is here, and it's not just pigs, they're gonna soar!!!?

Analysis below.

1. Sponsored by CITIC and Morgan Stanley, the big brother Yingen also had this combination, resulting in nearly 100% gains in both the gray market and the first day. Little Yingen will also ride the wave. (The only thing to note is that Morgan Stanley doesn't play tricks, so if you're betting on tricks, goodbye.)

2. The cornerstone investors account for 50%, meaning there will be less anchoring, and the selling pressure in the gray market and on the first day won't be too heavy. Plus, the cornerstone investors are all big names—follow them, and you won't go wrong.

3. The company's technology has core competitiveness: LBL-024 (globally unique), LBL-007 (third globally), LBL-034 (second globally).

4. Calculated using the price-to-research ratio, a valuation of 6 billion is very reasonable. Yingen is at 30 billion, and Yaojie at 12.6 billion. Good quality at a low price.

5. The margin financing is almost at 2000, it's really heating up.

6. Hong Kong's innovative drug stocks have been rising like crazy recently.

7. The Hang Seng Index broke through today—shouldn't it rally to celebrate?

There's a drug tariff at the end of the month, but it has nothing to do with Linton. Linton is small-scale, trading is not continuous, and NewCo can fully handle all policy risks. Drug licensing isn't counted in the trade deficit, and with the upcoming Sino-US leaders' meeting, they won't target China's innovative drug BD at this juncture.

My strategy: Go for B, one account.

The subscription deadline is tomorrow—whether I strike it rich depends on tonight.$Hang Seng Index(00HSI.HK) $Hang Seng TECH Index(STECH.HK) $LEADS BIOLABS-B(09887.HK)